Lakefront Biotherapeutics (LKFT) Free Cash Flow (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Free Cash Flow of -$110.6 million for Q1 2026, down 177.53% year-over-year from $142.7 million in Q1 2025, and up 6.86% quarter-over-quarter from -$118.8 million in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Free Cash Flow (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Free Cash Flow for 13 consecutive years, with -$110.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 177.53% year-over-year to -$110.6 million; the TTM figure through Mar 2026 stood at -$221.4 million (down 33.74% YoY), while the FY2025 annual figure was -$374.4 million, up 19.28% from the prior year.
- Free Cash Flow advanced to -$110.6 million in Q1 2026 per LKFT's latest filing, from -$118.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $4.7 million in Q2 2025 and bottomed at -$231.7 million in Q4 2022.
- Historically, Free Cash Flow has averaged -$81.6 million across 5 years, with a median of -$99.6 million in 2023.
- Annual changes were most pronounced in 2025 — Free Cash Flow soared 71.99% — and 2026, when it slumped 177.53%.
- Lakefront Biotherapeutics' Free Cash Flow stood at -$231.7 million in 2022, then jumped by 39.34% to -$140.5 million in 2023, then grew by 4.72% to -$133.9 million in 2024, then grew by 11.29% to -$118.8 million in 2025, then increased by 6.86% to -$110.6 million in 2026.
- Business Quant data shows LKFT's Free Cash Flow at -$110.6 million in Q1 2026, -$118.8 million in Q4 2025, and $3.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -96.74 Mn |
| Dec 31, 2025 | -53.38 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Jun 30, 2025 | 4.70 Mn |
| Mar 31, 2025 | -35.25 Mn |
| Dec 31, 2024 | -57.65 Mn |
| Sep 30, 2024 | 4.65 Mn |
| Jun 30, 2024 | 3.58 Mn |
| Mar 31, 2024 | -128.94 Mn |
| Dec 31, 2023 | -416.67 Mn |
| Mar 31, 2023 | -97.25 Mn |
| Dec 31, 2022 | -482.74 Mn |
| Mar 31, 2022 | -59.25 Mn |
| Dec 31, 2021 | -514.35 Mn |
| Jun 30, 2021 | -85.50 Mn |
| Mar 31, 2021 | -135.97 Mn |
| Dec 31, 2020 | -458.81 Mn |
| Jun 30, 2020 | -148.27 Mn |
| Mar 31, 2020 | -72.87 Mn |
| Dec 31, 2019 | -108.20 Mn |